<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-0DCFWZBB/f5422cff-47a8-4ae4-af6c-ce067f63b7d1/HTML"><dcterms:extent>40 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-0DCFWZBB/293d78df-123b-4990-9873-f61f81865534/PDF"><dcterms:extent>1039 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-0DCFWZBB/6a25f8ae-1100-411f-88c4-5e4dafb01071/TEXT"><dcterms:extent>20 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-0DCFWZBB"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2010</dcterms:issued><dc:creator>Vranič, Andrej</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:44</dc:format><dc:format xml:lang="sl">6 strani</dc:format><dc:format xml:lang="sl">str. 107-112, IV</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:27119065</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-0DCFWZBB</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">antigeni</dc:subject><dc:subject xml:lang="sl">Antigeni novotvorb</dc:subject><dc:subject xml:lang="en">Antigens, Neoplasm</dc:subject><dc:subject xml:lang="en">Cathepsins</dc:subject><dc:subject xml:lang="en">Immunohistochemistry</dc:subject><dc:subject xml:lang="sl">Imunohistokemija</dc:subject><dc:subject xml:lang="sl">Katepsini</dc:subject><dc:subject xml:lang="en">Meningeal Neoplasms</dc:subject><dc:subject xml:lang="sl">Meningealne novotvorbe</dc:subject><dc:subject xml:lang="en">Meningeom</dc:subject><dc:subject xml:lang="en">Meningioma</dc:subject><dc:subject xml:lang="sl">meningiomi</dc:subject><dc:subject xml:lang="en">Neoplasm Recurrence, Local</dc:subject><dc:subject xml:lang="sl">Novotvorba, ponovitev lokalna</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="sl">Receptorji progesteronski</dc:subject><dc:subject xml:lang="en">Receptors, Progesterone</dc:subject><dc:subject xml:lang="en">Retrospective Studies</dc:subject><dc:subject xml:lang="sl">Retrospektivne študije</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Antigen expression on recurrent meningioma cells|</dc:title><dc:description xml:lang="sl">Introduction. Meningiomas are intracranial brain tumours that frequently recur. Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported. The most important prognostic factors for meningioma recurrenceare meningioma grade, meningioma invasiveness and radicality of neurosurgical resection. The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas. Methods. 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry. Results. MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001). No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed. Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p&lt;0.001) were both higher in the recurrent than in the non-recurrent meningioma group. Conslusions. MIB-1 antigen expression is higher in recurrentcompared to non-recurrent meningiomas. There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas. Cathepsins B and L are expressed more in recurrent meningiomas</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-0DCFWZBB"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-0DCFWZBB" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-0DCFWZBB/293d78df-123b-4990-9873-f61f81865534/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-0DCFWZBB/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-0DCFWZBB" /></ore:Aggregation></rdf:RDF>